ArticleNature2021
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 271 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
271citing papers in PubMed, 3 pooled it
24.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
271 citing papers in PubMed, 3 syntheses or guidelines pooled it, 422 citations in OpenAlex.
- Impact of temperature and humidity on SARS-CoV-2 transmissibility: a systematic review and meta-analysis.Frontiers in public health · 2025Pooled it
- Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Pooled it
- Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2023Pooled it
- Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).Microbiology spectrum · 2024Trial
- Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Trial
- Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants.Clinical and translational science · 2023Trial
- Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.Lancet (London, England) · 2023Trial
- Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.Annals of internal medicine · 2022Trial
- Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals.Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology · 2022Trial
- Sustainable Biocatalytic Cascades: A Versatile Tool in the Synthesis of Natural Products With Therapeutic Potential.Chembiochem : a European journal of chemical biology · 2026Review
- Substrate and target selectivity of 4'-fluoroadenosine against viral and host polymerases.The Journal of biological chemistry · 2026Article
- Triple IFN pathway deficiency sensitizes mice to human respiratory virus infection independent of human viral receptor expression.Nature communications · 2026Article
- Coronavirus M Protein Hijacks Toll-Interacting Protein (TOLLIP) to Suppress NF-κB Signaling and Promote Immune Evasion.MedComm · 2026Article
- Inhibitors Targeting SARS-CoV-2 Papain-Like Protease: Screening, Design, Synthesis, and Biological Evaluation.ChemMedChem · 2026Article
- Adult Stem Cell-Derived Intestinal Organoids as In Vitro Models of High-Fat Diet-Related Intestinal Diseases.Biomolecules · 2026Article
- MELK inhibition disrupts actin cytoskeleton and broadly restricts human coronavirus infections.Nature communications · 2026Article
- Uridine cytidine kinases govern molnupiravir bioactivation and anti-SARS-CoV-2 activity.PLoS pathogens · 2026Article
- Recent advances in the construction of humanized animal models and applications in translational medicine.Animal models and experimental medicine · 2026Review
- Combination Therapeutic Effect of Antibacterial and Antiviral Agents on Feline Chronic Gingivostomatitis Nonbounded to Prior Tooth Extraction Confirmed by Physical Signs and Clinical Biomarkers.Veterinary sciences · 2026Article
211 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
26 authors at 2 institutions in 1 country.
Angela Wahl *International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lisa E Gralinski *Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Claire E JohnsonInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0003-0048-6592
Wenbo YaoInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Martina KovarovaInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kenneth H DinnonDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-8942-1551
Hongwei LiuDepartment of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Victoria J MaddenMicroscopy Services Laboratory, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-7909-7743
Halina M KrzystekDepartment of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Chandrav DeInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kristen K WhiteMicroscopy Services Laboratory, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kendra GullyDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-5742-2341
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Tanzila ZamanDepartment of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Sarah R LeistDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Paul O GrantDepartment of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-6640-6415
Gregory R BluemlingEmory Institute of Drug Development (EIDD), Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-9138-7578
Alexander A KolykhalovEmory Institute of Drug Development (EIDD), Emory University, Atlanta, GA, USA.
Michael G NatchusDrug Innovation Ventures at Emory (DRIVE), Atlanta, GA, USA.
Frederic B AskinDepartment of Pathology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
George PainterEmory Institute of Drug Development (EIDD), Emory University, Atlanta, GA, USA.
Edward P BrowneDivision of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Corbin D JonesDepartment of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Raymond J PicklesDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-6827-8701
J Victor GarciaInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. victor_garcia@med.unc.edu.ORCID http://orcid.org/0000-0003-3726-0482
University of North Carolina at Chapel Hill · USEmory University · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MVirology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9MUnlocking Zika Virus Immune Control and Pathogenesis with the Collaborative CrossU19AI100625 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, HEISE, MARK T · 2012 to 2021
$36.6MDeterminants of Coronavirus Fidelity in Replication and PathogenesisR01AI108197 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BARIC, RALPH S, DENISON, MARK R · 2013 to 2022
$6.5MNext generation ultra-long acting antiretroviral formulations for HIV treatment and preventionR01AI140799 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARCIA-MARTINEZ, J. VICTOR · 2018 to 2022
$3.9MThe Role of Human Gut Microbiota in HIV-1 Rectal Acquisition, Replication, and PathogenesisR01AI123010 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WAHL, ANGELA RAQUEL · 2016 to 2020
$3.7MRole of Myeloid Cells in HIV latency in the Periphery and the CNSR01MH108179 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARCIA-MARTINEZ, J. VICTOR · 2015 to 2019
$2.7MPlug & Purge: In Vivo Targeting of Active HIV Reservoirs That Persist Despite ARTR01AI111899 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARCIA-MARTINEZ, J. VICTOR · 2014 to 2018
$2.5MGenetically Engineered Hamsters as Small Animal Models for Testing RSV TherapeuticsR21AI138247 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PICKLES, RAYMOND J · 2018 to 2019
$425kRSV, Keratins and Distal Airway InfectionR21AI113736 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PICKLES, RAYMOND J · 2015 to 2016
$418kNCI NIH HHS P30 CA016086NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI108197NIAID NIH HHS R01 AI111899NIAID NIH HHS R01 AI123010NIAID NIH HHS R01 AI140799NIAID NIH HHS R21 AI113736NIAID NIH HHS R21 AI138247NIAID NIH HHS U19 AI100625NIMH NIH HHS R01 MH108179
Abstract
All coronaviruses known to have recently emerged as human pathogens probably originated in bats
Indexed as
COVID-19 Drug TreatmentAdministration, OralAlveolar Epithelial CellsAnimalsChemopreventionChiropteraClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCOVID-19CytidineCytokinesEpithelial CellsFemaleHeterograftsHumansHydroxylaminesCytidineCytokinesHydroxylaminesInterferon Type Imolnupiravir
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.